

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
30.8	Thiamine	Tablet 100 mg	Per Tablet						Number of Companies consisting of Market Share of 1% & Above		206.08	
									Sum of MAT value considered for price calculation (in Lakhs)		3.72	
									PTR under Consideration		17.21%	
									% Reduction with compared to Highest Price (average)		0.64	
									Reduction as per Monopoly condition		3.08	
									PTR after Reduction		0.49	
									Add : 16% Retailer Margin		3.57	
									Ceiling Price (without local taxes) (wef. 10.3.2016)		0.10	
									WPI Reduction wef 1.4.2016 @ -2.7105%		3.47	
									S.O. 619(E) dated 26.02.2015			
									Ceiling Price as per NLEM 2011	4.32	Per Tablet	
									Derived Ceiling PTR	3.72		
									S.O. 619(E) dated 26.02.2015			
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)			
A. List of Item Under consideration									TOTAL MAT	2,06,14,798	100.00%	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	30.8	VITAMIN B1 PLAIN (WITH ADDITIVES) A11E13	BENALGIS 100 MG TABLET 10	BENALGIS	FRANCO INDIAN PHARMACEUTICALS PVT LTD	100 MG	10	TABLET	50.17	2,06,07,735	99.97%	3.72
		VITAMIN B1 PLAIN (WITH ADDITIVES) A11E13	THYMINE 100 MG TABLET 10	THYMINE	SYNOKEM PHARMACEUTICALS LTD	100 MG	10	TABLET	35.00	7,063	0.03%	
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Thiamine	Injection 100 mg/ml		Injection	1561 (E) dated 27.4.2016	17.21						
					Average Reduction	17.21						

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013													
Number of Companies consisting of Market Share of 1% & Above										1			
6.4.3.2.2	Nevirapine	Oral Liquid 50mg/5ml	Per ML	Sum of MAT value considered for price calculation (in Lakhs)							0.25		
PTR under Consideration										0.78			
% Reduction with compared to Highest Price (average)										12.75%			
Reduction as per Monopoly condition										0.10			
PTR after Reduction										0.68			
Add : 16% Retailer Margin										0.11			
Ceiling Price (without local taxes) (wef. 10.3.2016)										0.79			
WPI Reduction wef 1.4.2016 @ -2.7105%										0.02			
S.O. 619(E) dated 26.02.2015										Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)		0.77	
Ceiling Price as per NLEM 2011			1.08	Per ML									
Derived Ceiling PTR			0.93										
A. List of Item Under consideration										TOTAL MAT		25,323	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)	
1	6.4.3.2.2	NEVIRAPINE J5B7	NEVIMUNE 50 MG SUSPENSION 10	NEVIMUNE	CIPLA LTD.	50 MG	100	ML	78.40	25,323	100.00%	0.78	
B. Computation of Average rate of Reduction under Monopoly													
	S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date					Reduction with reference to the highest PTR under NLEM 2015 (%)		
	1	Nevirapine	Tablet 200 mg	Tablet		1253(E) dated 29.3.2016					12.75		
										Average Reduction		12.75	

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											1	
30.1	Ascorbic acid (Vitamin C)	Tablet 100 mg	Per Tablet						Number of Companies consisting of Market Share of 1% & Above			
									Sum of MAT value considered for price calculation (in Lakhs)		37.41	
									PTR under Consideration		0.11926	
									% Reduction with compared to Highest Price (average)		11.90%	
									Reduction as per Monopoly condition		0.01419	
									PTR after Reduction		0.10507	
									Add : 16% Retailer Margin		0.01681	
									Ceiling Price (without local taxes) (wef. 10.3.2016)		0.12188	
									WPI Reduction wef 1.4.2016 @ -2.7105%		0.00330	
									Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)		0.11858	
									S.O. 836(E) dated 25.3.2015			
									Ceiling Price as per NLEM 2011	0.19	Per Tablet	
									Derived Ceiling PTR	0.16		
A. List of Item Under consideration									TOTAL MAT	37,40,828		
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	30.1	PLAIN VITAMIN C (INCLUDING VITAMIN C SALTS) A11X31	CELIN 100 MG TABLET 1000	CELIN	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	100 MG	1000	TABLET	119.26	37,40,828	100.00%	0.11926
B. Computation of Average rate of Reduction under Monopoly												
	S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date						Reduction with reference to the highest PTR under NLEM 2015 (%)
	1	Ascorbic acid (Vitamin C)	500mg tablet		tablet	Proposed in current 39th meeting						11.90
						Average Reduction						11.90

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
										Number of Companies consisting of Market Share of 1% & Above	1	
23.3	Neostigmine	Tablet 15 mg	Per Tablet							Sum of MAT value considered for price calculation (in Lakhs)	117.31	
										PTR under Consideration	4.12	
										% Reduction with compared to Highest Price (average)	7.01%	
										Reduction as per Monopoly condition	0.29	
										PTR after Reduction	3.83	
										Add : 16% Retailer Margin	0.61	
										Ceiling Price (without local taxes) (wef. 10.3.2016)	4.44	
										WPI Reduction wef 1.4.2016 @ -2.7105%	0.12	
										S.O. 619(E) dated 26.02.2015		
										Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	4.32	
										Ceiling Price as per NLEM 2011	5.11	
										Derived Ceiling PTR	4.41	
A. List of Item Under consideration										TOTAL MAT	1,17,30,918	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	23.3	NEOSTIGMINE N7C10	TILSTIGMIN 15 MG TABLET 10	TILSTIGMIN	TABLETS INDIA LTD	15 MG	10	TABLET	41.22	1,17,30,918	100.00%	4.12
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Neostigmine	Injection 0.5 mg/ml		Injection	Proposed in current 39th meeting	7.01						
					Average Reduction	7.01						

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013													
										Number of Companies consisting of Market Share of 1% & Above		1	
12.2.2	Amiodarone	Injection 50 mg/ml	Per ML							Sum of MAT value considered for price calculation (in Lakhs)		20.41	
										PTR under Consideration		18.71	
										% Reduction with compared to Highest Price (average)		13.82%	
										Reduction as per Monopoly condition		2.59	
										PTR after Reduction		16.12	
										Add : 16% Retailer Margin		2.58	
										Ceiling Price (without local taxes) (wef. 10.3.2016)		18.70	
										WPI Reduction wef 1.4.2016 @ -2.7105%		0.51	
										S.O. 619(E) dated 26.02.2015			
										Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)		18.19	
			Ceiling Price as per NLEM 2011	22.92	Per ML								
			Derived Ceiling PTR	19.76									
A. List of Item Under consideration											TOTAL MAT	20,40,805	100.00%
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)	
1	12.2.2	AMIODARONE C1B3	RITEBEAT 50 MG INJECTION 2 ML	RITEBEAT	TORRENT PHARMACEUTICALS LTD.	50 MG	2	ML	53.94	1,22,552	6.01%	19.76	
		AMIODARONE C1B3	RITEBEAT IV 50 MG INJECTION 3 ML	RITEBEAT	TORRENT PHARMACEUTICALS LTD.	50 MG	3	ML	52.95	19,18,253	93.99%	17.65	
B. Computation of Average rate of Reduction under Monopoly													
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)							
1	Amiodarone	200 mg Tablet		Tablet	1819 (E) dated 18.5.2016	9.52							
2	Amiodarone	100 mg Tablet		Tablet	2195(E) dated 23.6.2016	18.12							
						Average Reduction	13.82						

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
										Number of Companies consisting of Market Share of 1% & Above	1	
6.4.1.1	Acyclovir	Oral liquid 400 mg/5 ml		Per ML						Sum of MAT value considered for price calculation (in Lakhs)	171.18	
										PTR under Consideration	1.21	
										% Reduction with compared to Highest Price (average)	13.91%	
										Reduction as per Monopoly condition	0.17	
										PTR after Reduction	1.04	
										Add : 16% Retailer Margin	0.17	
										Ceiling Price (without local taxes) (wef. 10.3.2016)	1.21	
										WPI Reduction wef 1.4.2016 @ -2.7105%	0.03	
										Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	1.18	
										S.O. 619(E) dated 26.02.2015		
		Ceiling Price as per NLEM 2011	1.45	Per ML								
		Derived Ceiling PTR	1.25									
A. List of Item Under consideration										TOTAL MAT	1,71,17,929	
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	PTR (Rs.)	MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	6.4.1.1	ACICLOVIR J5A4	ZOVIRAX 400 MG SUSPENSION 100 ML	ZOVIRAX	GLAXOSMITHKLINE PHARMACEUTICALS LTD.	400 MG	100	ML	121.01	1,71,17,929	100.00%	1.21
B. Computation of Average rate of Reduction under Monopoly												
S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packaging, if any	S.O. number & date	Reduction with reference to the highest PTR under NLEM 2015 (%)						
1	Acyclovir	Tablet 200 mg		tablet	2195(E) dated 23.6.2016	13.62						
2	Acyclovir	Tablet 400 mg		tablet	2195(E) dated 23.6.2016	5.15						
3	Acyclovir	Powder for Injection 250 mg		Powder for Injection	<u>Proposed in current 39th meeting</u>	28.25						
4	Acyclovir	Powder for Injection 500 mg		Powder for Injection	<u>Proposed in current 39th meeting</u>	8.63						
						Average Reduction	13.91					

Computation of Ceiling Price based on Aug 2015 Data under Para 6 of DPCO 2013												
											Number of Companies consisting of Market Share of 1% & Above	1
12.1.3	Diltiazem	Injection 5 mg/ml	Per ML								Sum of MAT value considered for price calculation (in Lakhs)	56.81
											PTR under Consideration	2.66
											% Reduction with compared to Highest Price (average)	2.73%
											Reduction as per Monopoly condition	0.07
											PTR after Reduction	2.59
											Add : 16% Retailer Margin	0.41
											Ceiling Price (without local taxes) (wef. 10.3.2016)	3.00
											WPI Reduction wef 1.4.2016 @ -2.7105%	0.08
											Final Ceiling Price (without local taxes) (wef. 01.4.2016 or date of notification, whichever is later)	2.92
											S.O. 619(E) dated 26.02.2015	
											Ceiling Price as per NLEM 2011	3.33
											Per ML	
											Derived Ceiling PTR	2.87
A. List of Item Under consideration												
S. No.	Unique No. as per NLEM	Composition as per NLEM	पैक विवरण Pack Description	छाप BRAND	कंपनी Company	Strength	Pack Size	Unit	TOTAL MAT PTR (Rs.)	56,81,061 MAT (Rs.)	MAT (%)	Price per Unit Considered (Rs.)
1	12.1.3	DILTIAZEM C8A6	DILZEM IV 5 MG INJECTION 5 ML	DILZEM	TORRENT PHARMACEUTICALS LTD.	5 MG	5	ML	13.28	56,81,061	100.00%	2.66
B. Computation of Average rate of Reduction under Monopoly												
		S. No.	Drug(s)	Strength	Description	Route of Administration/ Dosage Form & packsize/packing, if any		S.O. number & date				Reduction with reference to the highest PTR under NLEM 2015 (%)
		1	Diltiazem	SR Tablet 90 mg		tablet		1253(E) dated 29.3.2016				3.28
		2	Diltiazem	Tablet 30 mg		tablet		2195(E) dated 23.6.2016				2.48
		3	Diltiazem	Tablet 60 mg		tablet		2195(E) dated 23.6.2016				2.43
											Average Reduction	2.73